Special Offer. Now 25% off the original price of $2500.
Sequencing of the 80,000 - 100,000 genes in the human genome is near completion. Gene therapy is one of the many applications of these newly sequenced genes. For at least the last ten years in the gene therapy field, scientists have been focused on trying to transfer a gene to a cell, have the cell uptake the gene, and then have the gene produce a protein. Researchers, however, have not yet discovered the technology that will allow them to climb the gene transfer step. Directly harvested cells, cultured cell lines, genetically modified cell lines, viral vectors, and liposomes are all methods researchers use for ex vivo gene therapy experiments and in vivo gene therapy clinical trials. Viral vectors and liposomes are two types of technologies that are being developed which are allowing academic, government, and industry researchers to find ways to successfully transfer a gene for gene therapy.

Various estimates and forecasts of the global gene therapy market range from $1 billion to $5 billion in the next five years. The gene therapy market is projected to be $12 billion as early as 2007. A projection of $45 billion dollars for the gene therapy market in 2010 indicates continued rapid growth. All of the gene therapy forecasts are dependent, however, on finding successful gene transfer methods and continued government and consumer support of gene therapy research. To date, gene therapy is still a developing field. Gene therapy is not yet a revenue generating product. At this time, more than thirty companies and twenty research centers are focused on developing viral vector and liposome gene transfer technology for gene therapy and DNA vaccine applications.

In this study focusing on viral vector and liposome gene therapy gene transfer methods, Kalorama will investigate the various viral vector and liposome, gene transfer methods, potential markets, the companies and research centers developing viral vector and liposome gene transfer methods, and any role government and/or public policy has on the development of viral vector and liposome gene transfer technology.

Related Reports:

SNP and Whole Genome Sequencing Market Research Bundle
Apr 1, 2010 - KLI2614026 - $5,995.00

SNP Genotyping and Analysis Markets and the Future of Personalized Medicine
Feb 1, 2010 - KLI2402105 - $3,995.00

The World Market for Biosimilars and the Potential for US Follow-on Biologics
Aug 1, 2009 - KLI2402283 - $3,700.00

DNA Sequencing Equipment and Services Markets, 2nd Edition
Aug 1, 2009 - KLI2122235 - $3,800.00

Cell Culture: The World Market for Media, Sera and Reagents, 2nd Edition
May 1, 2009 - KLI2091313 - $3,995.00

Pharmacodiagnostics and Personalized Medicine 2009 (Markets, Challenges, Forecasts and Key Players)
Apr 1, 2009 - KLI2128157 - $3,500.00

Stem Cell Therapeutics Markets
Feb 1, 2009 - KLI2021959 - $2,500.00

Pharmaceutical Outsourcing Post-Launch : Contract Manufacturing, Biomanufacturing and Sales, 3rd Edition
Jan 1, 2009 - KLI1646605 - $3,500.00

Biophotonics: A Strategic Assessment of Photonics Technologies for Biomedical Applications, 2nd Edition
Dec 1, 2008 - KLI1928788 - $3,995.00

Key Genetic Technologies Market Research Bundle (SNPs, Gene Expression Profiling, DNA Sequencing and Analytical Chips)
Nov 1, 2008 - KLI1689637 - $7,995.00